Form 4: MAXCYTE Director Cynthia Collins Receives Annual Equity Grant

MAXCYTE, Inc. Director Cynthia Collins was granted 29,210 Restricted Stock Units and 50,790 stock options as part of her annual compensation, according to a recent SEC Form 4 filing.

Summary

• Cynthia Collins, a Director of MAXCYTE, INC. (MXCT), acquired 29,210 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 18, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs were granted at a price of $0 and will vest on June 18, 2026, contingent upon Ms. Collins' continuous service.
• Following this transaction, Ms. Collins beneficially owns 80,889 shares of Common Stock directly.
• Additionally, Ms. Collins was granted 50,790 stock options with an exercise price of $2.11 per share on June 18, 2025.
• These stock options were granted at a price of $0, became exercisable on June 18, 2025, and will expire on June 17, 2035.
• Following this transaction, Ms. Collins beneficially owns 50,790 derivative securities (stock options) directly.
• Both the RSU and stock option grants were made pursuant to MAXCYTE's Equity Grant Policy for non-employee directors.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates routine compensation and aligns director interests with shareholders, without any negative sales or unexpected events.

Positives

• The equity grants align the director's interests with those of shareholders, as her compensation is tied to the company's stock performance.
• The grants are part of a standard annual compensation policy for non-employee directors, indicating routine corporate governance.

Negatives

• The grants represent a slight potential for future share dilution when RSUs vest and options are exercised, though this is typical for equity compensation.

Risks

• The vesting of the 29,210 Restricted Stock Units is subject to Cynthia Collins' continuous service as a director until June 18, 2026.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the vesting schedule for the granted equity.

Industry Context

This filing reflects a standard practice within the biotechnology and life sciences industries, where equity compensation, including restricted stock units and stock options, is a common component of remuneration for non-employee directors to align their interests with long-term company performance and shareholder value.

Corporate Governance

Related Party Transactions

• The acquisition of 29,210 Restricted Stock Units and 50,790 stock options by Cynthia Collins, a director of MAXCYTE, INC., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grants represent a potential for minor future dilution upon vesting of RSUs and exercise of options, but also serve to align the director's interests with shareholder value creation.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The transaction is a standard compensation practice for non-employee directors, reflecting established corporate governance.

Next Steps

• The 29,210 Restricted Stock Units are scheduled to vest on June 18, 2026, contingent on Cynthia Collins' continuous service.
• The 50,790 stock options are exercisable as of June 18, 2025, and will expire on June 17, 2035.

Key Dates

Recommendation

Keywords

MAXCYTE, MXCT, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Corporate Governance, Biotechnology, Life Sciences